Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7

6 clinical trials · Condition

Record	Firm	Date
Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer (NCT03575234)	Emory University	2020-07-01
Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer (NCT03468218)	Emory University	2018-09-18
ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment (NCT02917629)	National Cancer Institute (NCI)	2018-05-31
Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma (NCT02775812)	National Cancer Institute (NCI)	2016-11-28
Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin (NCT02381535)	National Cancer Institute (NCI)	2015-10-22
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck (NCT01064479)	M.D. Anderson Cancer Center	2010-02-05

Every clearance here is in the API, with alerts when new ones post.